Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.00 (0.00%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £20.17m
IHC Live PriceLast checked at - London Stock Exchange

Intraday Inspiration Hlt Share Chart

Distribution agreement for AIHL test

24 Apr 2020 07:00

RNS Number : 7231K
Genedrive PLC
24 April 2020
 

genedrive plc

("genedrive" or the "Company")

 

Distribution agreement for AIHL test

 

 Inspiration Healthcare to distribute genedrive's Antibiotic Induced Hearing Loss test in UK & Ireland

Option to expand agreement to engage Inspiration Healthcare's global neonatal sub-distributor network

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a contract for the distribution of the Company's Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland with Inspiration Healthcare Group plc (AIM: IHC) ("Inspiration Healthcare"). The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's specialty network of over 50 neonatal focussed sub-distributors around the world.

 

David Budd, Chief Executive Officer of genedrive plc, said: "Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought leading healthcare company with a specialist emphasis on neonatal care. Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together."

 

The Genedrive® MT-RNR1 test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics. In the UK, 90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. Genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK's National Institute of Clinical Excellence (NICE).

 

Neil Campbell, Chief Executive Officer of Inspiration Healthcare, commented: "We are delighted to be able to work with genedrive plc with this novel testing device for new born babies that could suffer hearing loss due to antibiotics given to them on admission into neonatal intensive care. Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."

 

genedrive plc

 

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, Antibiotic Induced Hearing Loss, and has tests in development for tuberculosis (mTB) and SARS-CoV-2.

 

About Inspiration Healthcare (http://www.inspiration-healthcare.com)

 

Inspiration Healthcare is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

 

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe. In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGREAELDAASEEAA
Date   Source Headline
16th Jun 20267:00 amRNSFinal Results
2nd Jun 20267:01 amRNSNotice of Results
2nd Jun 20267:00 amRNSTransfer of Non-Core Products to Focus on Neonatal
14th Apr 20267:00 amRNSChange of Adviser
16th Mar 20269:33 amRNSHolding(s) in Company
16th Mar 20269:33 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSUK neonatal division wins NHS framework agreement
26th Feb 20269:23 amRNSHolding(s) in Company
12th Feb 20267:00 amRNSFull year trading update
10th Feb 20269:05 amRNSHolding(s) in Company
3rd Feb 20267:00 amRNSAppointment of Joint Broker
2nd Feb 202611:01 amRNSHolding(s) in Company
28th Jan 20261:40 pmRNSHolding(s) in Company
28th Jan 20267:00 amRNSPurchasing agreement in the US
27th Jan 20269:46 amRNSHolding(s) in Company
26th Jan 202610:02 amRNSHolding(s) in Company
22nd Jan 20261:37 pmRNSHolding(s) in Company
26th Nov 20257:00 amRNSChange of auditor
16th Oct 20251:51 pmRNSHolding(s) in Company
7th Oct 20257:00 amRNSHalf-year Report
23rd Sep 20257:00 amRNSResults presentations for analysts and investors
19th Sep 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNSTrading update and notice of results
24th Jul 20251:37 pmRNSResult of AGM
24th Jul 20257:00 amRNSAGM Statement
13th Jun 20259:16 amRNSPublication of AR, accounts & notice of AGM
6th Jun 20257:00 amRNSBoard Change
28th May 20257:00 amRNSUnaudited Preliminary results
23rd May 20257:00 amRNSNotice of Results
15th May 20255:01 pmRNSHolding(s) in Company
15th May 202510:06 amRNSHolding(s) in Company
1st Apr 202511:36 amRNSHolding(s) in Company
21st Mar 20252:49 pmRNSGrant of Options
12th Mar 20256:01 pmRNSHolding(s) in Company
12th Mar 20256:00 pmRNSDirector/PDMR Shareholding
24th Feb 20254:16 pmRNSDirector/PDMR Shareholding
21st Feb 20252:52 pmRNSDirector/PDMR Shareholding
18th Feb 20257:00 amRNSTrading update
10th Feb 20259:54 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSDirectorate Change
14th Jan 20254:08 pmRNSHolding(s) in Company
12th Dec 20247:00 amRNSAppointment of Chief Executive Officer
14th Nov 20247:00 amRNSBoard Change
4th Nov 20247:00 amRNSGrant of Covenant Waiver and Covenant Reset
2nd Oct 20247:00 amRNSHalf-year Report
17th Sep 202412:26 pmRNSResult of AGM
3rd Sep 20247:00 amRNSTrading update for the six months to 31 July 2024
5th Aug 20243:41 pmRNSHolding(s) in Company
2nd Aug 20247:00 amRNSNominated adviser and broker
31st Jul 20243:29 pmRNSPublication of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.